{"id":"W4411017560","doi":"10.1016/j.esmoop.2025.105120","title":"Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; University of California, San Francisco; Eisai; Daiichi-Sankyo; Veracyte; Genentech; NSABP Foundation; Les Laboratories Pierre Fabre; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche; Seagen; Roche","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Quality of life (healthcare); Adjuvant; Randomized controlled trial; Internal medicine; Cancer; Adjuvant therapy; Endocrine system; Gynecology; Metastatic breast cancer; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001477114,0.0002856838,0.00168052,0.0001782826,0.0000456623,0.00003565399,0.0004549298,0.00008668164,0.0001175645],"category_scores_gemma":[0.0001948582,0.0001707168,0.0001169712,0.0005900926,0.0004161309,0.0001947786,0.0001474224,0.000349628,8.709343e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008623493,"about_ca_system_score_gemma":0.0005854673,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02693647,"about_ca_topic_score_gemma":0.008341453,"domain_scores_codex":[0.9971234,0.0008096864,0.0009106075,0.0004149189,0.000420445,0.0003209511],"domain_scores_gemma":[0.9979518,0.0008802618,0.0003711868,0.0005713505,0.0001501451,0.00007524456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8317622,0.0004960517,0.1289652,0.0001434928,0.0003991531,0.00001464757,0.002892409,0.00001517663,0.0002026752,0.0006060751,0.00003571485,0.03446723],"study_design_scores_gemma":[0.623229,0.0002760227,0.3737358,0.0004729995,0.0000454071,0.00001063922,0.0004184498,0.00001617295,0.0003020632,0.0005717271,0.0007787794,0.0001430058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869167,0.001309595,0.00005808127,0.005298729,0.000175776,0.004798533,0.00007017308,0.00001694198,0.001355511],"genre_scores_gemma":[0.995733,0.001478894,0.0003186206,0.001144334,0.00009247881,0.0008074174,0.00001253417,0.00002719636,0.0003855373],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2447706,"threshold_uncertainty_score":0.9795433,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03120879118476509,"score_gpt":0.3602247273950173,"score_spread":0.3290159362102522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}